Friday, October 19, 2018 10:28:56 PM
New press coverage of the 2-73 Alzheimer's trial in Australia per TTTav66:
https://www.9news.com.au/2018/10/19/18/29/dementia-pill-clinical-trial-anavex-2-73
Australian press covering the 2-73 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772297
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143773822
Apologies and thanks to the poster who first posted this article, having trouble keeping up with the good news:
https://www.yourlifechoices.com.au/health/news/alzheimers-trial-delivers-results
UK press covering the 2-73 trial (repeat of AU coverage):
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772909
_________________________________________________________________________________________
Link to the CTAD conference program, October 24-27:
http://www.ctad-alzheimer.com/files/files/CTAD%2011th%20Final%20Program%20-%2017%20oct%20BD-1.pdf
CTAD presentations of interest, from the above:
Poster available during the duration of CTAD:
P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the
Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen Macfarlane, MBBS FRANZCP1 , Michael Kornhauser BPharm1 , Ella Modini BSc1 , Harald Hampel, MD PhD2 , Stephan Toutain MS3, Christopher Missling PhD3
Friday, October 26 - Late Breaking Session
3.30 - 3.45 p.m. LB9 - Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers
Harald Hampel, MD, PhD1 , Mohammad Afshar, MD, PhD2 , Frédéric Parmentier, PhD2 , Coralie Williams, MSc2 , Adrien Etcheto, MSc2 , Federico Goodsaid, PhD3 , Christopher U Missling, PhD4
****Information on Federico Goodsaid,Regulatory Pathfinders
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143696879
https://www.linkedin.com/in/regulatory
pathfinders (Thanks blanka)
Saturday, October 27- Oral communications:
1.30 - 1.45 p.m. OC31 - TRC-PAD: Accelerating participant recruitment in AD clinical trials through innovation Gustavo A. Jimenez-Maggiora, MBA1 , Rema Raman, PhD1 , Michael S. Rafii, MD, PhD1 , Reisa Anne Sperling, MD2,3, Jeffrey Lee Cummings, MD4, Paul S. Aisen, MD1
_________________________________________________________________________________________
Hampel SPEAKS!....
htps://investorshub.advfn.com/boards/read_msg.aspx?message_id=142864055
Slides:
https://www.anavex.com/wp-content/uploads/2018/07/Anavex-AAIC-2018-DT-01-Presentation.pdf
_________________________________________________________________________________________
Hampel SPEAKS AGAIN!.... at the VI International Congress on Research and Innovation in Neurodegenerative Diseases:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143924640
Comments on the above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921147
_________________________________________________________________________________________
Dec. 11 NYAS symposium, Alzheimer’s Disease Therapeutics: Alternatives to Amyloid, Nell Rebowe with Dr. Rudy Tanzi and Dr. Howard Fillit of the Alzheimers's Drug Discovery Foundation
_https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143979620
________________________________________________________________________________________
Anavex SAB member Dr Paul Aisen speaks about PET Scans:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921781
_________________________________________________________________________________________
Dr Robert Lisak’s MS poster presented at the 2018 ECTRIMS conference:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144223191&txt2find=ectrims
_________________________________________________________________________________________
An excellent summary of why we are here from poster sokol:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143320176
Short term milestone summary:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144330988
CRISPER discover of likely MOA for 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144274561
From dadofmarcmax, the linked site has TONS of info:
"Why does Anavex 2-73 have effects on seemingly different neurodegenerative disorders? What makes it so special? "
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143816865
Missling has a strategy - one poster's read of that strategy:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144051610
Charts showing periods of institutional accumulation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144037184
Basic biology concepts for Alzheimer’s disease
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137348423
Alzheimer's and Sleep:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134772774
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134771894
Dangerous medicines and mitochondrial dysfunction:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142393634&txt2find=mitochondrial
Shareholder meeting report:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140128467&txt2find=shareholder|meeting
What is a Special Protocol Assessment?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140087471
Precision Medicine and “The Economics of Drug Development”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144010889
Arguments for accelerated approval for 2-73.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143620275
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143624077
Missling states that PET scans will be used in P2/3 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143981335
How the Parkinson's Dementia trial may help expedite Alzheimer's approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143580569
Perspective on how quickly Anavex could morph into a profitable entity , making further dilution unnecessary. This may provide urgency for institutions to establish a position where stock has limited liquidity resulting in a pre-approval ramp up of pricing.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143560772
AVXL 2-73 and cerebral blood flow:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143582952
Anavex and Ariana (thanks TTAV66)
"Ariana Pharma promoting their work with Anavex. Nice write up, including the further reading section where they point to the upcoming CTAD presentation and detail their full history of collaboration with Anavex. "
http://www.arianapharma.com/2018/09/alzheimer-precision-medicine/
Of Mice and Men - Alzheimer's drug development through the years:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143978495
Brain cells from stem cells at Lund University:
https://www.lunduniversity.lu.se/article/new-method-grows-brain-cells-from-stem-cells-quickly-and-efficiently
Dr. Tangui Maurice on the Sigma 1 - 2015 video:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143980208
Dr. Tanzi on infection and Alzheimer's, also "soda brain".
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143979877
Did BIIB blink?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143525102
Anavex - Biogen & MS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143729928
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143732818
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143734046
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144040837
Recent AVXL News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:06 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:31:07 PM
- Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/07/2024 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM